Ioversol , otherwise known as IOU peroxide, is used as a dialysis
anticoagulant in hospitals for the treatment of dialysis patients and is used
commercially for the treatment of toothache. It is an oxidizing agent for
internal applications in the human body. The Ioversol chemical name is
Isoflavones and contains seven carbon atoms with one hydrogen atom in common
with many substances derived from plants (Isoflavones). Isoflavones are
commonly found in fruits such as strawberry and lemon, and also in egg yolk and
some vegetables, notably artichokes, parsley, beets, carrots, leek, and kidney
beans. Ioversol (Iodine-Orient-containing Nutrient suspension) is generally
used for the relief of inflammation and to treat infections, to prevent or
reduce bleeding, as dialysis therapy and to increase blood flow and oxygenate
blood
The growing prevalence of bone-related disorders is a prime
factor driving the growth of the ioversol
market.
Increasing geriatric population around the globe which is increasing the
prevalence of the various chronic disease. This has raised the demand for a
various diagnostic tool such as X-ray which is another key factor fueling the
growth of the market. According to the United Nation, by 2050, one in six
people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%).
By 2050, one in four persons living in Europe and Northern America could be
aged 65 or over. The rise in spending on the healthcare sector by government
for improving the patient care is further anticipated to propel the growth of
the ioversol market.
North America is projected to gain significant growth over
the forecast period and this is attributed to the high prevalence of the bone-related
disorder in the region which. In 2017, the number of Canadians affected by
osteoporosis had increased to 2 million. By the year 2030, the number of hip
fractures is expected to quadruple. Moreover, In Canadians of 40 years or
older, 1.5 million (10%) reported having been diagnosed with osteoporosis. Thus
the high prevalence of bone a related disorder is projected to foster the
growth of the ioversol market.
Key Developments:
1. In December 2020, Guerbet (GBT), a global provider of
medical imaging, announced that it received US Food and Drug Administration
approval for the commercial sale of the Optiray® Imaging Bulk Package (IBP)
(Ioversol Injection) in the United States.